Method of treatment
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon BIEMANS, Dominique BOUTRIAU, Philippe DENOEL, Pierre DUVIVIER, Carine GORAJ
Life of this patent
Estimating the term…
Loading patent…
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon BIEMANS, Dominique BOUTRIAU, Philippe DENOEL, Pierre DUVIVIER, Carine GORAJ
Estimating the term…
The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the pH of the composition is pH 5.0-pH 8.0. The application further discloses an immunogenic composition comprising; (i) a S. aureus Type 5 capsular saccharide conjugated to a carrier protein, (ii) a S. aureus Type 8 capsular saccharide conjugated to a carrier protein, (iii) a ClfA protein or immunogenic fragment thereof, (iv) an alpha toxoid, and (v) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0
A method of treating or preventing a Staphylococcus aureus infection in a human patient, comprising administering to the patient a single dose of an immunogenic composition comprising;
A method of treating or preventing a Staphylococcus aureus infection in a human patient, comprising administering to the patient a single dose of an immunogenic composition comprising;
An immunogenic composition comprising;
Dependencies are inferred from the claim text.